Skip to content

Intestinal Microbiota in Stem Cell Transplant Transplant Admission

Intestinal Microbiota Alteration by Antibiotics Used During Stem Cell Transplant Admission

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04623424
Enrollment
255
Registered
2020-11-10
Start date
2020-11-03
Completion date
2028-11-03
Last updated
2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stem Cell Transplant Complications

Brief summary

In this prospective study, the primary objective will be to investigate the association between the use of antibiotics administered during the admission period of Stem cell transplant (SCT) and the rate of overall change in microbiota composition across adjacent samples in time.

Detailed description

Early preclinical studies suggested that intestinal microflora contribute to aGVHD and may be relapse. There is increasing evidence that use of antibiotics may have a detrimental impact on intestinal microbiota composition and, consequently, the outcome of SCT.However, effect on different antibiotic prophylaxis regimens and broad-spectrum antibiotics used during transplant and the intestinal microbiota composition and hence adverse outcomes are not known. Stool samples will be collected from patients who are undergoing SCT at: 1. preconditioning 2. at day 0 (stem cell infusion) 3. once in the period of day + 7-10 post SCT 4. once first day or second day of BMT OPD clinic visit 5. once if they develop \>=grade I GVHD 6. once at time of recovery from GVHD

Interventions

DIAGNOSTIC_TESTintestinal microbiota

Stoll samples will be tested for different bacteria

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18-80 years * patients undergoing allogenic or autologous SCT for malignant hematological conditions or bone marrow failure

Design outcomes

Primary

MeasureTime frame
Changes in microbiomeUp to 6 months post stem cell transplant

Countries

United States

Contacts

CONTACTshatha farhan, MD
SFARHAN1@HFHS.ORG313 916 5002
PRINCIPAL_INVESTIGATORshatha farhan

Henry Ford

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026